Insulin increases CSF Aβ42 levels in normal older adults
Abstract
Background: Abnormal insulin metabolism may contribute to the clinical symptoms and pathophysiology of AD. In vitro studies show that insulin enhances the release of β-amyloid protein (Aβ) or inhibits its degradation, either of which might increase amyloid burden.
Methods: On separate mornings, 16 healthy older adults (10 women, 6 men; mean age 68.7 years, SD 8.6 years) each underwent two infusions consisting of either saline (placebo) or insulin (1.0 mU·kg−1·min−1) plus dextrose to maintain euglycemia. After 120 minutes of infusion, blood, CSF, and cognitive measures were acquired.
Results: As expected, insulin infusion produced an increase in CSF insulin concentration. Insulin infusion also led to an increase in CSF Aβ42 levels, most notably in older subjects. As has been observed previously, insulin infusion facilitated declarative memory, but such facilitation was attenuated in the subjects with the greatest increase in CSF Aβ42 levels.
Conclusions: These findings are consistent with recent in vitro studies of insulin effects on Aβ and support the notion that insulin may modulate Aβ42 levels acutely in humans.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Leibson C, Rocca W, Hanson V, et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci . 1997; 826: 422–427.
2.
Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol . 1997; 145: 24–32.
3.
Craft S, Asthana S, Schellenberg GD, et al. Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology . 1999; 70: 146–152.
4.
Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology . 1998; 50: 164–168.
5.
Gasparini L, Gouras GK, Wang R, et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and required mitogen-activated rotein kinase signaling. J Neurosci . 2001; 21: 2561–2570.
6.
Authier F, Posner BI, Bergeron JJM. Insulin-degrading enzyme. Clin Invest Med . 1996; 19: 149–160.
7.
Kurochkin IV, Goto S. Alzheimer’s B-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett . 1994; 345: 33–37.
8.
McDermott JR, Gibson AM. Degradation of Alzheimer’s beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res . 1997; 22: 49–56.
9.
Qiu W, Walsh D, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem . 1998; 273: 32730–32738.
10.
Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid B-protein via proteolysis by insulin-degrading enzyme. J Neurosci . 2000; 20: 1657–1665.
11.
Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry . 2002; 41: 1091–1099.
12.
Edbauer D, Willem M, Lammich S, Steiner H, Haass C. Insulin-degrading enzyme rapidly removes the β-amyloid precursor protein intracellular domain (AICD). J Biol Chem 2002;.
13.
Perez A, Morelli L, Cresto JC, Castano EM. Degradation of soluble amyloid B-peptides 1–40, 1–42, and the Dutch variant 1–40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res . 2000; 25: 247–255.
14.
Cook DG, Leverenz J, Ericksen S, et al. Reduced hippocampal insulin degrading enzyme in late onset Alzheimer’s disease is associated with the apolipoprotein E-ε 4 allele. Am J Pathol . 2003; 162: 313–319.
15.
Baskin D, Figlewicz D, Woods S, Porte D, Dorsa D. Insulin in the brain. Annu Rev Physiol . 1987; 49: 335–347.
16.
Baura GD, Foster DM, Porte D Jr, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest . 1993; 92: 1824–1830.
17.
Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev . 1992; 13: 387–414.
18.
Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer’s disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry . 1999; 56: 1135–1140.
19.
Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav . 2000; 68: 509–514.
20.
Craft S, Asthana S, Cook DG, et al. Insulin dose–response effects on memory and plasma APP in Alzheimer’s disease: interactions with ApoE genotype. Psychoneuroendocrinology, in press.
21.
Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in dementia of the Alzheimer type. Neurobiol Aging . 1996; 17: 123–130.
22.
Kern W, Peters A, Fruehwald–Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology . 2001; 74: 270–280.
23.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res . 1975; 12: 189–198.
24.
Storandt M, Hill RD. Very mild senile dementia of the Alzheimer’s type II. Psychometric test performance. Arch Neurol . 1989; 46: 383.
25.
Perret E. The left frontal lobe of man and the suppression of habitual responses in verbal categorical behavior. Neuropsychologia . 1974; 12: 323–330.
26.
Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese–American men: impact of obesity. J Clin Endocrinol Metab . 1995; 80: 1399–1406.
27.
Mehta PD, T. P, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer’s disease. Neurosci Lett 2001;304:102–106.
28.
Sjogren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res . 2001; 66: 510–516.
29.
Jensen M, Schroder J, Blomberg M, et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol . 1999; 45: 504–511.
30.
Andreasen N, Blennow K. β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides . 2002; 23: 1205–1214.
31.
Tong L, Thornton PL, Balazs R, Cotman CW. β-Amyloid-(1–42) impairs activity-dependent cAMP response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem . 2001; 276: 17301–17306.
32.
Westerman MA, Cooper–Blacketer D, Mariash A, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci . 2002; 22: 1858–1867.
33.
Wang H-W, Pasternak JF, Kuo H, et al. Soluble oligomers of β amyloid (1–42) inhibit long term potentiation but not long term depression in rat dentate gyrus. Brain Res . 2002; 924: 133–140.
Information & Authors
Information
Published In
Copyright
© 2003.
Publication History
Received: April 4, 2002
Accepted: February 17, 2003
Published online: June 24, 2003
Published in print: June 24, 2003
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus, International Journal of Molecular Sciences, 24, 14, (11301), (2023).https://doi.org/10.3390/ijms241411301
- Effects of Diabetes Mellitus-Related Dysglycemia on the Functions of Blood–Brain Barrier and the Risk of Dementia, International Journal of Molecular Sciences, 24, 12, (10069), (2023).https://doi.org/10.3390/ijms241210069
- Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer’s Disease, Biomolecules, 13, 2, (232), (2023).https://doi.org/10.3390/biom13020232
- A Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease, Current Molecular Medicine, 23, 9, (889-900), (2023).https://doi.org/10.2174/1566524023666230529093314
- Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin, Scientific Reports, 13, 1, (2023).https://doi.org/10.1038/s41598-023-33674-2
- Diabetes and cognitive dysfunction, Neurobiology of Brain Disorders, (185-201), (2023).https://doi.org/10.1016/B978-0-323-85654-6.00027-7
- Alzheimer’s Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer’s Disease and Type 2 Diabetes, International Journal of Molecular Sciences, 23, 5, (2687), (2022).https://doi.org/10.3390/ijms23052687
- A Bioinformatics Approach Toward Unravelling the Synaptic Molecular Crosstalk Between Alzheimer’s Disease and Diabetes, Journal of Alzheimer's Disease, 86, 4, (1917-1933), (2022).https://doi.org/10.3233/JAD-215059
- HMGB1 signaling pathway in diabetes-related dementia: Blood-brain barrier breakdown, brain insulin resistance, and Aβ accumulation, Biomedicine & Pharmacotherapy, 150, (112933), (2022).https://doi.org/10.1016/j.biopha.2022.112933
- Influence of genetic and cardiometabolic risk factors in Alzheimer’s disease, Ageing Research Reviews, 81, (101723), (2022).https://doi.org/10.1016/j.arr.2022.101723
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.